Protagonist Therapeutics (NASDAQ: PTGX) is a Newark, California-based clinical-stage biopharmaceutical company whose disulfide-rich peptide platform has produced two lead therapeutic programs of consequence for the peptide space: rusfertide (Mimrylo, the FDA-approved hepcidin mimetic for polycythemia vera) and icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen for autoimmune disease).
The most consequential recent event was the Friday August 28, 2026 FDA approval of Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera, based on the Phase 3 VERIFY trial (76.9% phlebotomy-free versus 32.9% for placebo). The approval triggered $275 million in payments from Takeda ($200 million opt-out fee plus $75 million approval milestone) under the January 2024 worldwide license and collaboration agreement. Protagonist retains tiered royalties on rusfertide sales. Jefferies projects Mimrylo peak sales potential of $2 billion.
Icotrokinra (an oral IL-23 receptor antagonist peptide developed with Janssen) is advancing in a broad autoimmune-disease Phase 3 program covering plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease indications; the oral peptide route is designed to compete with the injectable IL-23 monoclonal antibody class (Skyrizi, Tremfya) on convenience and cost. Protagonist's preclinical pipeline extends across additional metabolic, inflammatory, and hematologic indications. Stories here cover platform readouts, partnership progression, and commercial ramp. See [[rusfertide]], [[icotrokinra]], and [[takeda]] for adjacent threads.
Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.
Protagonist Therapeutics (Nasdaq: PTGX) and Takeda are presenting four rusfertide abstracts at the 2026 European Hematology Association Congress in Stockholm (June 11-14), including analyses from the Phase 3 VERIFY study and long-term results from the Phase 2 REVIVE and THRIVE open-label extensions. The 32-week VERIFY primary analysis showed 76.9% of patients on rusfertide achieved a clinical response versus 32.9% on placebo; the 52-week dataset met the primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class subcutaneous hepcidin-mimetic peptide for polycythemia vera. The FDA accepted the rusfertide NDA in early 2026 with priority review and set a Q3 2026 PDUFA target action date.